Aurobindo Pharma gains 12% after USFDA issued EIR for Hyderabad facility

The stock is trading higher for the fourth straight day and has rallied 38 per cent during the period.

Shares of Aurobindo Pharma gained 12 per cent to Rs 406 on the BSE on Friday, after the company announced that its Hyderabad-based facility has received an Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAl) status from the US FDA. The stock of drugmaker was trading higher for the fourth straight day and has rallied 38 per cent during the period.

“The company’s Unit VIII, active pharmaceutical ingredient (API) manufacturing facility located at Gaddapotharam, Hyderabad, has received the Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAl) status from the United States Food and Drug Administration (US FDA),”